WHWK News & Events

Reports Q4 revenue $0, consensus $20M. Cash, cash equivalents and short-term investments as of December 31, 2025, were $145.7M vs. $47.2M as of December 31, 2024. Cash is anticipated to fund operations into 2028 based on current plans. "Last year marked our evolution into Whitehawk Therapeutics, a boldly pragmatic company developing the next generation of ADC cancer treatments. We progressed three programs through IND-enabling work in tandem, while building the capabilities required to execute efficiently in the clinic as we enter 2026," said CEO Dave Lennon. "Whitehawk combines established but underexploited tumor targets with a differentiated ADC platform. With two active Phase 1 studies for HWK-007 and HWK-016, and a third IND submission for HWK-206 planned mid-year, we are energized by the opportunity to translate our strategy into clinical data with the potential to have a meaningful impact for patients."

Whitehawk Therapeutics announced that the U.S. FDA has cleared the Investigational New Drug application for HWK-007, its PTK7-targeted ADC. Whitehawk's Phase 1 trial for HWK-007 is now actively recruiting and will initially evaluate activity in lung and ovarian cancers, two PTK7-expressing tumor types with established precedent data, as well as endometrial cancer, one of the highest PTK7-expressing tumor types. The company also announced the submission of an IND for HWK-016, its MUC16-targeted ADC, to the FDA in December 2025. A Phase 1 trial is anticipated to start recruiting this quarter and is expected to initially evaluate activity in two high MUC16-expressing gynecologic cancers, ovarian and endometrial. Both next-generation ADC programs leverage Whitehawk's advanced ADC technology platform consisting of a highly stable yet cleavable linker that delivers a DNA Topoisomerase I inhibitor payload. Whitehawk expects to report initial clinical data from these trials in early 2027.